Skip to content

Acupuncture for Anxiety in Parkinson's Disease

Acupuncture as a Symptomatic Treatment for Anxiety in Parkinson's Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04729010
Enrollment
30
Registered
2021-01-28
Start date
2021-10-31
Completion date
2024-05-31
Last updated
2021-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Parkinson Disease

Keywords

Acupuncture, Anxiety, Parkinson's Disease

Brief summary

This is a single-center, double-blind, placebo-controlled trial to see if acupuncture can safely and effectively manage anxiety in Parkinson's Disease. Eligible subjects will receive either real or sham acupuncture THREE times weekly for a total of SIX weeks.

Interventions

OTHERAcupuncture to treat anxiety in Parkinson disease

Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.

Sponsors

Xiamen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed with Parkinson's Disease by authorized Neurologist. * Patients 40-75 years of age * Patients who have significant anxiety symptom * Patients must be on a stable medication regimen for the treatment of PD

Exclusion criteria

* Patients who have had previous acupuncture within the past SIX months * Patients with dementia, depression, or sleep disorder * Patients who are currently taking medications known to affect anxiety

Design outcomes

Primary

MeasureTime frameDescription
Change in the Hamilton Anxiety Scale (HAM-A) between the treatment group.SIX weeksThe primary outcome measure will be the change between the baseline visit and the SIX-week time point in the Hamilton Anxiety Scale (HAM-A) between the treatment group. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity, and 25-30 moderate to severe.
Change in the Generalized Anxiety Disorder 7-Item (GAD-7) scale between the treatment group.SIX WeeksThe primary outcome measure will be the change between the baseline visit and the SIX-week time point in the Generalized Anxiety Disorder 7-Item (GAD-7) scale between the treatment group. Each item is scored on a scale of 0 (not at all) to 3 (Nearly Every Day), with a total score range of 0-56, where \<4 indicates Minimal Anxiety, 5-9 Mild Anxiety, 10-14 Moderate Anxiety, and 15-21 Severe Anxiety.

Secondary

MeasureTime frameDescription
Change in the Unified Parkinson's Disease Rating Scale between the treatment group.THREE monthsA comprehensive assessment of both motor and non-motor symptoms associated with Parkinson's. The Unified Parkinson's Disease Rating Scale is made up of 42 items. These items are divided into six sections which are separately evaluation of mentation, behavior, and mood, self-evaluation of the activities of daily life, clinician-scored monitored motor evaluation, complications of therapy, Hoehn and Yahr staging of severity of Parkinson's disease and Schwab and England ADL scale. The evaluation score for the first item to the 39th item is 0 to 4 points. The evaluation score for the 40th to the 42th item is 0 to 1 points. The higher score means the worse condition. This scores indicate severe symptoms.

Contacts

Primary ContactYun Jin Kim, Ph.D
neurokim@gmail.com603-87055098

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026